Cited by 158RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvancements in Transdermal Drug Delivery

Lipid nanoparticles for short interfering RNA delivery

Open access
Leung, Alex K.K., Tam, Yuen Yi C., Cullis, Pieter R.·2014·Advances in genetics

Abstract

The discovery of RNA interference (RNAi) in mammalian cells has created a new class of therapeutics based on the reversible silencing of specific disease-causing genes. This therapeutic potential depends on the ability to deliver inducers of RNAi, such as short-interfering RNA (siRNA) and micro-RNA (miRNA), to cells of target tissues. This chapter reviews various challenges and delivery strategies for siRNA, with a particular focus on the development of lipid nanoparticle (LNP) delivery technologies. Currently, LNP delivery systems are the most advanced technology for systemic delivery of siRNA, with numerous formulations under various stages of clinical trials. We also discuss methods to improve gene silencing potency of LNP-siRNA, as well as application of LNP technologies beyond siRNA to the encapsulation of other nucleic acids such as mRNA and clustered regularly interspaced short palindromic repeats (CRISPR).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/b978-0-12-800148-6.00004-3

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The success of the first approved siRNA-LNP therapeutic and mRNA COVID-19 vaccines originates only from their delivery using ionizable lipid-containing LNPs.

    “Based on the potential toxicity of liposomes in clinical application,25,26 the success of the first approved small interfering RNA-lipid nanoparticle (LNP) therapeutic27 and mRNA COVID-19 vaccines originates only from their delivery using ionizable lipid-containing LNPs,28, 29, 30”

    From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [28]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R.
Affiliations
University of British Columbia (CA)
Corresponding author
Cullis, Pieter R.
Venue
Advances in genetics
Publisher
Elsevier
Published
2014
Volume
88
Pages
71-110
ISSN
0065-2660 (ISSN-L)
OpenAlex
W2399800494
Cited by
158
References
177
Citations by year
2026: 9 · 2025: 18 · 2024: 11 · 2023: 25 · 2022: 21 · 2021: 13 · 2020: 12 · 2019: 16 · 2018: 15 · 2017: 6 · 2016: 9 · 2015: 3
FWCI
7.59
Type
book chapter
Language
en
Open access
Locations
  • Advances in genetics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
lipid nanoparticles, siRNA delivery, RNA interference, gene silencing, systemic siRNA delivery, microRNA, mRNA encapsulation, CRISPR delivery, nucleic acid delivery systems
MeSH terms
Animals, Clinical Trials as Topic, Humans, Lipids, Genetic Therapy, Gene Transfer Techniques, Gene Silencing, RNA Interference, RNA, Small Interfering, Nanoparticles, Clustered Regularly Interspaced Short Palindromic Repeats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review